Salem Al-Tamemi1, Shafiq Ur Rehman Naseem2, Nabila Al-Siyabi3, Ibtisam El-Nour2, Abdulhakim Al-Rawas2, David Dennison4. 1. Department of Child Health, Sultan Qaboos University Hospital, PO Box 96, PC 123 SQU Al-Khod, Muscat, Oman. tamemi@squ.edu.om. 2. Department of Child Health, Sultan Qaboos University Hospital, PO Box 96, PC 123 SQU Al-Khod, Muscat, Oman. 3. Directorate of Nursing, Sultan Qaboos University Hospital, Muscat, Oman. 4. Department of Hematology, Sultan Qaboos University Hospital, Muscat, Oman.
Abstract
PURPOSE: Primary immunodeficiency (PID) diseases are rare, complex medical disorders that often are overlooked in clinical settings. There are emerging reports of PID from Middle Eastern populations. This study describes the features of PID patients in a tertiary care setting in Oman and compares them with regional and worldwide reports. METHOD: Sultan Qaboos University Hospital (SQUH) is an academic tertiary care-level hospital for specialized healthcare, including PID patients. At the time of diagnosis, patients' sociodemographics, clinical features, laboratory investigations, and management were entered in electronic form. This study included patients seen between August 2005 and July 2015. RESULTS: One hundred forty patients were registered with a minimum estimated population prevalence of 7.0/100,000. The male/female ratio was 1.6:1, the median age of onset of symptoms was 8 months, and diagnosis was 21 months with a delay of 13 months. Family history was positive in 44 %, consanguinity was present in 76 %, death of a previous sibling was present in 36 %, and there was an overall mortality in 18 %, with an 85 % probability of survival 10 years following diagnosis. The most common type of immunodeficiency was phagocytic disorders (35.0 %), followed by predominantly antibody disorders (20.7 %), combined immunodeficiency (17.8 %), other well-defined PID syndromes (15.0 %), immune dysregulation syndromes (3.5 %), complement deficiencies (3.5 %), and unclassified immunodeficiency (4.2 %). The commonest presenting infection was pneumonia (47.1 %). CONCLUSION: PID is not a rare condition in Oman. The prevalence is in concordance with reports from the region but higher than in Western populations. The findings of the current study would help to improve the awareness and management of, and policy making for PID.
PURPOSE:Primary immunodeficiency (PID) diseases are rare, complex medical disorders that often are overlooked in clinical settings. There are emerging reports of PID from Middle Eastern populations. This study describes the features of PID patients in a tertiary care setting in Oman and compares them with regional and worldwide reports. METHOD: Sultan Qaboos University Hospital (SQUH) is an academic tertiary care-level hospital for specialized healthcare, including PID patients. At the time of diagnosis, patients' sociodemographics, clinical features, laboratory investigations, and management were entered in electronic form. This study included patients seen between August 2005 and July 2015. RESULTS: One hundred forty patients were registered with a minimum estimated population prevalence of 7.0/100,000. The male/female ratio was 1.6:1, the median age of onset of symptoms was 8 months, and diagnosis was 21 months with a delay of 13 months. Family history was positive in 44 %, consanguinity was present in 76 %, death of a previous sibling was present in 36 %, and there was an overall mortality in 18 %, with an 85 % probability of survival 10 years following diagnosis. The most common type of immunodeficiency was phagocytic disorders (35.0 %), followed by predominantly antibody disorders (20.7 %), combined immunodeficiency (17.8 %), other well-defined PID syndromes (15.0 %), immune dysregulation syndromes (3.5 %), complement deficiencies (3.5 %), and unclassified immunodeficiency (4.2 %). The commonest presenting infection was pneumonia (47.1 %). CONCLUSION: PID is not a rare condition in Oman. The prevalence is in concordance with reports from the region but higher than in Western populations. The findings of the current study would help to improve the awareness and management of, and policy making for PID.
Authors: Waleed Al-Herz; Mohammad E Zainal; Hamid M Alenezi; Khalid Husain; Salem H Alshemmari Journal: Asian Pac J Allergy Immunol Date: 2010 Jun-Sep Impact factor: 2.310
Authors: Beatriz E Marciano; Chiung-Yu Huang; Gyan Joshi; Nima Rezaei; Beatriz Costa Carvalho; Zoe Allwood; Aydan Ikinciogullari; Shereen M Reda; Andrew Gennery; Vojtech Thon; Francisco Espinosa-Rosales; Waleed Al-Herz; Oscar Porras; Anna Shcherbina; Anna Szaflarska; Şebnem Kiliç; Jose L Franco; Andrea C Gómez Raccio; Persio Roxo; Isabel Esteves; Nermeen Galal; Anete Sevciovic Grumach; Salem Al-Tamemi; Alisan Yildiran; Julio C Orellana; Masafumi Yamada; Tomohiro Morio; Diana Liberatore; Yoshitoshi Ohtsuka; Yu-Lung Lau; Ryuta Nishikomori; Carlos Torres-Lozano; Juliana T L Mazzucchelli; Maria M S Vilela; Fabiola S Tavares; Luciana Cunha; Jorge A Pinto; Sara E Espinosa-Padilla; Leticia Hernandez-Nieto; Reem A Elfeky; Tadashi Ariga; Heike Toshio; Figen Dogu; Funda Cipe; Renata Formankova; M Enriqueta Nuñez-Nuñez; Liliana Bezrodnik; Jose Gonçalo Marques; María I Pereira; Viviana Listello; Mary A Slatter; Zohreh Nademi; Danuta Kowalczyk; Thomas A Fleisher; Graham Davies; Bénédicte Neven; Sergio D Rosenzweig Journal: J Allergy Clin Immunol Date: 2014-04 Impact factor: 10.793
Authors: Waleed Al-Herz; Janet Chou; Ottavia Maria Delmonte; Michel J Massaad; Wayne Bainter; Riccardo Castagnoli; Christoph Klein; Yenan T Bryceson; Raif S Geha; Luigi D Notarangelo Journal: Front Immunol Date: 2019-01-15 Impact factor: 7.561
Authors: Nashat Al Sukaiti; Khwater Ahmed; Jalila Alshekaili; Mahmood Al Kindi; Matthew C Cook; Tariq Al Farsi Journal: Front Immunol Date: 2021-01-15 Impact factor: 7.561
Authors: Tariq Al Farsi; Sanjeewani Weerakoon; Jalila Mohsin; Hussein Al Mashayakhi; Khawater Ahmed; Amal Al Maani; Khuloud Aboqusida; Nashat Al Sukaiti Journal: Oman Med J Date: 2021-11-30
Authors: Hiba Mohammed Shendi; Amna Ali Al Kuwaiti; Ahmed Darwaish Al Dhaheri; Suleiman Al-Hammadi Journal: Front Immunol Date: 2022-01-31 Impact factor: 7.561